These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 20826182)

  • 41. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
    Gazitt Y; Freytes CO; Akay C; Badel K; Calandra G
    Stem Cells Dev; 2007 Aug; 16(4):657-66. PubMed ID: 17784839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.
    Dar A; Schajnovitz A; Lapid K; Kalinkovich A; Itkin T; Ludin A; Kao WM; Battista M; Tesio M; Kollet O; Cohen NN; Margalit R; Buss EC; Baleux F; Oishi S; Fujii N; Larochelle A; Dunbar CE; Broxmeyer HE; Frenette PS; Lapidot T
    Leukemia; 2011 Aug; 25(8):1286-1296. PubMed ID: 21494253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
    Liles WC; Broxmeyer HE; Rodger E; Wood B; Hübel K; Cooper S; Hangoc G; Bridger GJ; Henson GW; Calandra G; Dale DC
    Blood; 2003 Oct; 102(8):2728-30. PubMed ID: 12855591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New agents in HSC mobilization.
    Domingues MJ; Nilsson SK; Cao B
    Int J Hematol; 2017 Feb; 105(2):141-152. PubMed ID: 27905003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.
    Di Giacomo F; Lewandowski D; Cabannes E; Nancy-Portebois V; Petitou M; Fichelson S; Romeo PH
    Haematologica; 2012 Apr; 97(4):491-9. PubMed ID: 22180429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CXCR4 in clinical hematology.
    Calandra G; Bridger G; Fricker S
    Curr Top Microbiol Immunol; 2010; 341():173-91. PubMed ID: 20397073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
    De Clercq E
    Antivir Chem Chemother; 2019; 27():2040206619829382. PubMed ID: 30776910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
    Cashen AF; Nervi B; DiPersio J
    Future Oncol; 2007 Feb; 3(1):19-27. PubMed ID: 17280498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.
    Drugs R D; 2007; 8(2):113-9. PubMed ID: 17324009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.
    Karpova D; Dauber K; Spohn G; Chudziak D; Wiercinska E; Schulz M; Pettit AR; Levesque JP; Romagnoli B; Patel K; Chevalier E; Dembowsky K; Bonig H
    Leukemia; 2013 Dec; 27(12):2322-31. PubMed ID: 24072044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
    Theiss HD; Vallaster M; Rischpler C; Krieg L; Zaruba MM; Brunner S; Vanchev Y; Fischer R; Gröbner M; Huber B; Wollenweber T; Assmann G; Mueller-Hoecker J; Hacker M; Franz WM
    Stem Cell Res; 2011 Nov; 7(3):244-55. PubMed ID: 21752744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
    Jantunen E; Varmavuo V; Valtola J
    Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization.
    Jørgensen AS; Daugvilaite V; De Filippo K; Berg C; Mavri M; Benned-Jensen T; Juzenaite G; Hjortø G; Rankin S; Våbenø J; Rosenkilde MM
    Commun Biol; 2021 May; 4(1):569. PubMed ID: 33980979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice.
    Welschinger R; Liedtke F; Basnett J; Dela Pena A; Juarez JG; Bradstock KF; Bendall LJ
    Exp Hematol; 2013 Mar; 41(3):293-302.e1. PubMed ID: 23178377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
    Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.
    Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Acta Haematol; 2016; 135(1):29-36. PubMed ID: 26303343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
    De Clercq E
    Mini Rev Med Chem; 2005 Sep; 5(9):805-24. PubMed ID: 16178723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stem Cell Mobilizers: Novel Therapeutics for Acute Kidney Injury.
    Xu Y; Zeng S; Zhang Q; Zhang Z; Hu X
    Curr Protein Pept Sci; 2017; 18(12):1195-1199. PubMed ID: 27634446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy.
    De Blasio A; Rossi L; Zappone E; Ortu La Barbera E; Salvatori R; Pacilli M; Carbone A; Zaccarelli E; Papa A; Tomao S
    Anticancer Drugs; 2013 Jul; 24(6):653-7. PubMed ID: 23698254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.